Genetic testing is recommended for CPVT-susceptibility genes—RyR2, CASQ2, CALM1-3, TRDN and TECRL—in all probands with a definitive clinical diagnosis of CPVT and may be considered in individuals with idiopathic ventricular fibrillation (VF) upon identification of an adrenergic trigger. This evidence concerns the gene TRDN and ventricular fibrillation.